Search

814 Result(s)
Sort by

FDA-approves-nintedanib-in-SSc-ILD

FDA-approves-nintedanib-in-SSc-ILD

FDA approves Ofev® as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
Who are we?

Who are we?

Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Zactran®

Zactran®

Depending on species indication (and country of registration), the product is for the treatment and metaphylaxis control of respiratory disease in cattle caused by key bacteria (Mannheimia, Pasteurella, Histophilus and Mycoplasma) and footrot disease
BULTAVO 3

BULTAVO 3

Indicated for bluetongue disease serotype 3 in sheep and cattle
Immunology

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
More Potential

More Potential

Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
Aftopor®/Aftovaxpur®/Aftovax®

Aftopor®/Aftovaxpur®/Aftovax®

FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
Striverdi® Respimat®

Striverdi® Respimat®

Maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
GPP: there is more than you see

GPP: there is more than you see

Generalized Pustular Psoriasis is a rare neutrophilic skin condition. Watch an animation to learn about its recurrent nature and how it affects people
Ofev®

Ofev®

Ofev® is a prescription medication used to treat people with idiopathic pulmonary fibrosis (IPF) systemic sclerosis-associated interstitial lung disease (SSc-ILD) and other chronic fibrosing interstitial lung diseases with a progressive phenotype
Spiolto® Respimat®

Spiolto® Respimat®

Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Phase II trials for patients with bronchiectasis

Phase II trials for patients with bronchiectasis

Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Vetera

Vetera

For vaccination of healthy horses as an aid in the prevention of diseases caused by the included antigens (US and Canada only).